Product Monograph - epgonline.org

More documents

Recommendations

Info

References References Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestogens used in oral contraceptives. Contraception 1988; 38: 325–32 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315–26 Korver T, Dieben T, Vree M, Edwards van Muijen A, Vromans L, van der Sanden A, van Osta G. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 mcg/day or levonorgestrel 30 mcg/day. Eur J Contracept Reprod Health Care 1998; 3: 169–78 Korver T, Klipping C, Heger-Mahn D, Duijkers I, van Osta G, Dieben T. Maintenance of ovulation inhibition with the 75 Ìg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12-hour delays in tablet-intake. Contraception, in press Krauss RM, Burkman RT. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992; 167: 1177–84 Kuhnz W, Pfeffer M, Al-Yacoub G. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum. J Steroid Biochem 1990; 35: 313–8 Lammers P, op ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70: 497–500 Landgren BM, Diczfalusy E. Hormonal effect of the 300 mcg norethisterone (NET) minipill. Contraception 1980; 21: 87–113 Landgren BM, Johannisson E, Masironi B, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Contraception 1982; 26: 567–85 Landgren BM, Oriowo MA, Diczfalusy E. Pharmacokinetic and pharmacodynamics investigations with vaginal devices releasing levonorgestrel at a constant, near zero-order rate. Contraception 1981; 24: 29–44 Lavy G, DeCherney AH. The hormonal basis of ectopic pregnancy. Clin Obstet Gynecol 1987; 30: 217–24 Lebech PE, Svendsen PA, Østergaard E, Koch F. The effects of small doses of megestrol acetate on the cervical mucus. Acta Obstet Gynecol Scand 1969; 48: 22–5 Levy RI, Feinleib M. Risk factors for coronary artery disease and their management. In: Braunwald E (ed.). Heart disease. Philadelphia: Saunders and Co., 1980: 1246–78 Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestogens: role of bias in observational research. Contraception 1996; 54: 5–13 (Erratum: Contraception 1996; 54: 121) Lewis MA, MacRae KD, Külh-Habich D. The differential risk of oral contraceptives: the impact of full exposure history. Pharmacoepidemiol Drug Saf 1998; 7(Suppl.2): 115–6 Lewis MA. MacRae KD, Külh-Habich D. Venous thromboembolism, oral contraceptive use and exposure history. Eur J Contracept Reprod Helath Care 1998; 3(Suppl.): 36 Lidegaard Ø. The influence of thrombotic risk factors when oral contraceptives are prescribed: a control-only study. Acta Obstet Gynecol Scand 1997; 76: 252–60 Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and myocardial infarction. A five-year nation-wide case-control study. Eur J Contracept Reprod Health 2000; 5(Suppl.1): 29 Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187–96. Lidegaard Ø, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996; 53: 135–9 Lunsen HW van. Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third-generation progestogens. Eur J Contracept Reprod Health Care 1996; 1: 39–45 Machin SJ, Mackie IJ, Guillebaud J. Factor V Leiden mutation, venous thromboembolism and combined oral contraceptive usage. Br J Fam Plann 1995; 21: 13–4 Madden S, Back DJ, Martin CA, Orme ML'E. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br J Clin Pharmacol 1989; 27: 295–9 Madden S, Back DJ, Orme ML'E. Metabolism of the contraceptive steroid desogestrel by human liver in vitro. J Steroid Biochem 1990; 35: 281–8 McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50(Suppl.1): 9–195 McFarland KF, Murtiashaw M, Baynes JW. Clinical value of glycosylated serum protein and glycosylated hemoglobin levels in the diagnosis of gestational diabetes mellitus. Obstet Gybecol 1984; 64: 516–8 Miller A. Dysmenorrhoea. A systematic approach to management. J Ped Obstet Gynecol 1997; Nov/Dec: 18–22 Moghissi KS, Syner FN, McBride LC. Contraceptive mechanism of microdose norethindrone. Obstet Gynecol 1973; 41: 585–94 Oberti C, Dabancens A, Garcia-Huidobro M, Rodriguez-Bravo R, Zanartu J. Low dosage oral progestogens to control fertility. II. Morphologic modifications in the gonad and oviduct. Obstet Gynecol 1974; 43: 285–94 Potter LS. How effective are contraceptives The determination and measurement of pregnancy rates. Obstet Gynecol 1996; 88(Suppl.3): 13–23 48 49
References References Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand 1988; 67: 171–4 Rice CF, Killick S, Dieben T. The effect of desogestrel 75 mcg and levonorgestrel 30 mcg on the endometrium and bleeding patterns over one year. Br J Obstet Gynaecol 1998; 105(Suppl.17): 114 Rice CF, Killick SR, Dieben T, Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 mcg and levonorgestrel 30 mcg daily. Hum Reprod 1999; 14: 982–5 Rice C, Killick S, Hickling D, Coelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 1996; 11: 737–40 Rodriguez G, Faundes-Latham A, Atkinson LE. An approach to the analysis of menstrual patterns in the critical evaluation of contraceptives. Stud Fam Plann 1976; 7: 42–51 Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997; 177: 707–15 Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health: an interim report from the oral contraceptive study of the Royal College of General Practitioners. London: Pitman Medical Publishers, 1974: 37–42 Skouby SO. Laboratory and clinical assessment of a new progestational compound desogestrel. A phase I study. Acta Obstet Gynecol Scand 1982; 111(Suppl.): 7–11 Spellacy WN, Buhi WC, Birk SA. The effects of norgestrel on carbohydrate and lipid metabolism over one year. Am J Obstet Gynecol 1976; 125(7): 984–6 Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83–8 Stone SC. Desogestrel. Clin Obstet Gynecol 1995; 38: 821–8 Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141–6 Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48–52 Timmer CJ, Srivastava N, Dieben ThOM, Cohen AF. Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette® and Liseta®. Eur J Drug Metabol Pharmacokin 1999; 24(4): 335–43 Timmer CJ, Srivastava N, Dieben ThOM, Cohen AF. Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette® and Liseta®. Eur J Drug Metabol Pharmacokin 1999; 24(4): 335–43 Trussell J, Kost K. Contraceptive failure in the United States: a critical review of the literature. Stud Fam Plann 1987; 18: 237–83 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 1986; 292: 526 Viinikka L. Metabolism of a new synthetic progestogen, Org 2969, by human liver in vitro. J Steroid Biochem 1979; 10: 353–7 Viinikka L, Ylikorkala O, Vihko R, Hasenack HG, Nieuwenhuyse H. Metabolism of a new synthetic progestogen, Org 2969, in female volunteers. The distribution and excretion of radioactivity after an oral dose of the labeled drug. Acta Endocrinol 1980; 93: 375–9 Viinikka L, Ylikorkala O, Vihko R, Wijnand HP, Booij M, Veen F van der. Metabolism of a new synthetic progestogen, Org 2969, in female volunteers. Investigations into the pharmacokinetics after and oral dose. Eur J Clin Pharmacol 1979; 15: 349–55 Weijers MJ. Desogestrel, a new progestational compound, and the liver. Arzneim Forsch 1983; 33: 774–6 Weisberg E. Prescribing oral contraceptives. Drugs 1995; 49: 224–31 Westhoff CL. Oral contraceptives and venous thromboembolism: should epidemiologic associations drive clinical decision making Contraception 1996; 54: 1–3 WHO Task Force on Oral Contraceptives. Effects of hormonal contraceptives on breast milk composition and infant growth. Stud Fam Plann 1988; 19: 361–9 Winkler UH, Howie H, Buehler K, Korver T, Geurts TBP, Coelingh Bennink HJT. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 mcg desogestrel or 30 mcg levonorgestrel. Contraception 1998; 57: 385–92 Winkler UH, Oberhoff C, Bier U, Schindler AE, Gillain D. Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open, randomized, parallel-group study. Int J Fertil Menopausal Stud 1995; 40: 260–8 Wright SW, Fotherby K, Fairweather F. Effect of daily small doses of norgestrel on ovarian function. J Obstet Gynaecol Br Commonw 1970; 77: 65–8 50 51
Page 1 and 2: Product Monograph ® indicates trad
Page 3 and 4: Contents Product Monograph 1 2 Intr
Page 5 and 6: Introduction A reliable alternative
Page 7 and 8: Pharmacodynamics Pharmacodynamics T
Page 9 and 10: Pharmacodynamics Pharmacodynamics a
Page 11 and 12: Contraceptive efficacy Contraceptiv
Page 13 and 14: 5 Acceptability ■ ■ ■ ■ The
Page 15 and 16: Acceptability Acceptability Trends
Page 17 and 18: Acceptability Acceptability TABLE 9
Page 19 and 20: 6 Use during lactation ■ ■ ■
Page 21 and 22: 7 Safety aspects ■ ■ ■ Ceraze
Page 23 and 24: Safety aspects Safety aspects Hemos
Page 25 and 26: 8 Summary The estrogen component of
Page 27: References References Coutinho EM,
Page 31 and 32: Summary of Product Characteristics
Page 33: Summary of Product Characteristics

Product Monograph - epgonline.org

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?